Application of Peptide-Based Prodrug Chemistry in Drug Development

  • Arnab De

Table of contents

  1. Front Matter
    Pages i-xii
  2. Arnab De
    Pages 1-13
  3. Arnab De
    Pages 23-29
  4. Arnab De
    Pages 31-51
  5. Arnab De
    Pages 53-60
  6. Back Matter
    Pages 61-89

About this book

Introduction

Macromolecular (specifically peptide-based) drugs could potentially be highly effective medicines. However they have a relatively short duration of action and variable therapeutic index. An example of such a peptide is Glucagon-like Peptide I which could potentially be used as a revolutionary drug for diabetes. This is because it stimulates insulin only when the blood glucose level is high thereby reducing the risk of hypoglycemia (a significant disadvantage of using insulin is that an insulin overdose is the single most potent cause of life-threatening hypoglycemia). However it’s short duration of action (half-life of 2 minutes in plasma) precludes its therapeutic use.

In this volume, the use of novel therapeutics like GLP1 as an alternative to tradition insulin-based drugs in diabetes is described. Application of Peptide-Based Prodrug Chemistry in Drug Development elucidates the traditional concept of prodrugs as “specialized non-toxic protective groups used in a transient manner to alter or to eliminate certain limiting properties in the parent small molecule” (IUPAC definition). It goes on to provide insight into how prodrugs of peptides (with GLP1 as an example) could be appropriately used to extend the biological half life, broaden the therapeutic index of macromolecules and improve the pharmacodynamics of such drugs.  Author explains the logic behind designing peptide prodrugs, synthetic procedures and bioassays to examine the conversion of the prodrug to the drug under therapeutic conditions. The prodrugs described slowly convert to the parent drug at physiological conditions of 37C and pH 7.2 driven by their inherent chemical instability without the need of any enzymatic cleavage. The diketopiperazine and diketomorpholine (DKP and DMP) strategies for prodrug conversion are demonstrated in detail with special emphasis on the chemical flexibility that it offers to develop prodrugs with variable time actions.

This book will be of useful to chemists, biochemists, medicinal chemists, biologists and people in the medical profession (doctors). It may be used in undergraduate classes but will certainly help post-graduate students and advanced professionals.

The author is grateful to Prof. Richard DiMarchi (Standiford H. Cox Professor of Chemistry and the Linda & Jack Gill Chair in Biomolecular Sciences at Indiana University) for valuable suggestions. The foreword for the book has been written by Prof. Jean Martinez, (Legion d'Honneur awarded by the French Republic; Professor of Chemistry and Medicinal Chemistry of the University of Montpellier, France; and Chairman of European Peptide Society, 2002-2010).

Keywords

Application Diabetes Drug development Hypoglycemia Kinetics Peptide-based Peptides Pharmacodynamics Prodrug

Authors and affiliations

  • Arnab De
    • 1
  1. 1.Hammer Health Sciences Center 1308, Department of MicrobiologyColumbia University Medical CenterNew YorkUSA

Bibliographic information

  • DOI https://doi.org/10.1007/978-1-4614-4875-4
  • Copyright Information The Author(s) 2013
  • Publisher Name Springer, New York, NY
  • eBook Packages Medicine
  • Print ISBN 978-1-4614-4874-7
  • Online ISBN 978-1-4614-4875-4
  • Series Print ISSN 1864-8118
  • Series Online ISSN 1864-8126
  • About this book
Industry Sectors
Pharma
Chemical Manufacturing
Biotechnology
Electronics
Consumer Packaged Goods